{
    "clinical_study": {
        "@rank": "33646", 
        "arm_group": {
            "arm_group_label": "Breast cancer patients", 
            "description": "This is a single arm study evaluating feasibility of evaluating gait and parameter changes in patients with early stage breast cancer undergoing adjuvant taxane chemotherapy."
        }, 
        "brief_summary": {
            "textblock": "Longitudinal Evaluation of Taxane induced neuropathy in early stage breast cancer."
        }, 
        "brief_title": "Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "A study assessing the feasibility of evaluating neuropathy symptoms prospectively using\n      testing of gate and balance parameters."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          -  Patients (men and women) diagnosed with breast cancer stages I-III initiating first\n             line adjuvant or neoadjuvant therapy with paclitaxel or docetaxel\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n          -  Patients with functional limitations due to musculoskeletal conditions can be\n             included, because these conditions are known to remain stable over the relatively\n             short duration of the study.\n\n          -  Concurrent standard and investigational agents are permissible with the standard\n             chemotherapy drugs.\n\n        Exclusion Criteria\n\n          -  Prior known chemotherapy or targeted therapy (for breast cancer or other malignancies\n             that is known to be associated with neuropathy in the last 12 months(platinum\n             therapy, bortezomib, vinblastine, etc.)\n\n          -  Prior taxane exposure at any time\n\n          -  Preexisting known diagnosis of any type of neuropathy prior to start of paclitaxel or\n             docetaxel chemotherapy\n\n          -  Pregnant or nursing women.\n\n          -  Unable to give informed consent.\n\n          -  Preexisting lower extremity amputation\n\n          -  Inability to walk or stand without assistance due to any condition\n\n          -  Neuropathic pain medications prior to start of study including gabapentin,\n             pregabalin, amytriptyline, and duloxetine (but initiation of neuropathic pain\n             medications during treatment are permissible)\n\n          -  Patients needing ambulatory assist devices\n\n          -  Back or lower extremity surgery in the last 6 months\n\n          -  Back or lower extremity surgery at any timepoint that interferes with gait and\n             balance per patient or provider report"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Men and women diagnosed with breast cancer stages I-III"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125019", 
            "org_study_id": "OSU-13010"
        }, 
        "intervention_browse": {
            "mesh_term": "Taxane"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Cancer", 
            "Taxane", 
            "Gait", 
            "Men", 
            "Women"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "link": {
            "description": "The Jamesline", 
            "url": "http://cancer.osu.edu"
        }, 
        "location": {
            "contact": {
                "email": "Maryam.lustberg@osumc.edu", 
                "last_name": "Maryam Lustberg, MD, MPH", 
                "phone": "614-293-8858"
            }, 
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43210"
                }, 
                "name": "Ohio State University Wexner Medical Center"
            }, 
            "investigator": {
                "last_name": "Maryam Lustberg, MD, MPH", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer", 
        "overall_contact": {
            "email": "Jamesline@osumc.edu", 
            "last_name": "Ohio State University Comprehensive Cancer Center", 
            "phone": "1-800-293-5066"
        }, 
        "overall_contact_backup": {
            "email": "maryam.lustberg@osumc.edu", 
            "last_name": "Maryam Lustberg, MD, MPH", 
            "phone": "614-293-8858"
        }, 
        "overall_official": {
            "affiliation": "Ohio State University Comprehensive Cancer Center", 
            "last_name": "Maryam Lustberg, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Identify gait and balance parameters that are affected by during adjuvant/neoadjuvant taxane (paclitaxel or docetaxel) chemotherapy.", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125019"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ohio State University Comprehensive Cancer Center", 
            "investigator_full_name": "Maryam Lustberg", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluate the natural history of changes in these gait and balance parameters and their relationships with validated self-reported assessment tools of CIPN such as CIPN-20 and TNS", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Identify gait and balance changes as a consequence of chemotherapy with paclitaxel or docetaxel in the laboratory measuring the motion of the entire body in three dimensions with great accuracy.", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Ohio State University Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ohio State University Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}